New kidney drug YK012 enters first human tests

This early-stage study tests a new drug, YK012, in 72 adults with primary membranous nephropathy, a kidney disease that causes protein leakage. The main goals are to check safety and how the body processes the drug, with a first look at whether it helps reduce protein in urine. Participants must be 18-80, have a confirmed diagnosis within 10 years, and meet specific kidney function criteria.